MERCK COZAAR GENERATING 25,000 SCRIPTS WEEKLY AFTER SIX MONTHS ON MARKET; FOSAMAX OFF TO QUICK START, COMPANY TELLS SECURITIES ANALYST MEETING
Executive Summary
Merck's angiotensin II inhibitor Cozaar is attracting about 8% of its initial prescriptions from previous users of Merck's ACE inhibitor Vasotec.